SCHEMBL618705

SCHEMBL618705

CCS(=O)(=O)N1CC=C(c2cnc(N)c(C(=O)Nc3nc4ccccc4[nH]3)n2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 5/20 0.44
PRKDC P78527 1/20 0.43
PKM P14618 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPK1 P28482 1/20 0.42
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
KLF5 Q13887 2/20 0.41
OPRK1 P41145 1/20 0.41
PRMT5 O14744 1/20 0.41
MAPT P10636 2/20 0.41
ATM Q13315 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CLK1 P49759 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL617695 0.83 ATR (0.62) ATRPRKDCPRMT5ATMCCNE2
SCHEMBL615057 0.82 ATR (0.58) ATRPRKDCATMCCNE2CCNE1
SCHEMBL615394 0.80 ATR (0.57) ATRPRKDCPRMT5ATM
SCHEMBL614657 0.78 ATR (0.44) ATRPRKDCALDH1A1NPC1RAB9A
SCHEMBL617161 0.78 ATR (0.44) ATRPRKDCCCNE2CCNE1CDK2
SCHEMBL617489 0.77 GSK3B (0.44) ATRPRKDCPRMT5ATMCCNE2
SCHEMBL617640 0.77 ATR (0.60) ATRPRKDCATMCCNE2CCNE1
SCHEMBL616275 0.77 PRMT5 (0.41) ATRPRKDCPRMT5ATMCCNE2
SCHEMBL616594 0.77 ATR (0.62) ATRPRKDCCCNE2CCNE1CDK2
SCHEMBL13138618 0.76 ATR (0.68) ATRPRKDCATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140113005-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-04-24 US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
EP-2370424-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2011-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140113005-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 ATR 1/4885PRKDC 6/4885PKM 771/4885
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 ATR 1/4885PRKDC 6/4885PKM 771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.